A number of research firms have changed their ratings and price targets for Recursion Pharmaceuticals (NASDAQ: RXRX):
- 10/19/2026 – Recursion Pharmaceuticals had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $8.00 price target on the stock.
- 10/17/2026 – Recursion Pharmaceuticals was upgraded by Wall Street Zen from “strong sell” to “sell”.
- 10/16/2026 – Recursion Pharmaceuticals was given a new $5.90 price target by Morgan Stanley.
- 10/15/2026 – Recursion Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 8/29/2026 – Recursion Pharmaceuticals was upgraded by Wall Street Zen from “strong sell” to “sell”.
Insider Activity
In other news, Director Blake Borgeson sold 50,000 shares of the business’s stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $4.84, for a total transaction of $242,000.00. Following the completion of the sale, the director directly owned 6,108,287 shares of the company’s stock, valued at $29,564,109.08. The trade was a 0.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 22,408 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $3.52, for a total value of $78,876.16. Following the completion of the transaction, the chief executive officer owned 2,072,890 shares in the company, valued at $7,296,572.80. This represents a 1.07% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 157,408 shares of company stock worth $643,576. Company insiders own 6.65% of the company’s stock.
Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.
Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.
Featured Stories
- Five stocks we like better than Recursion Pharmaceuticals
- 5 Beaten-Down AI Names That Could Bounce If Fear Fades
- Could AI Finally Unlock Apple’s Next Leg of Growth?
- Women Drive the Job Market—These 3 Stocks Are Following Them
- 2026’s ETF Boom Is Approaching 2,000 Launches: Watch These 3
Receive News & Ratings for Recursion Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
